BBIO vs ENSG: fair value comparison
BridgeBio Pharma, Inc. and The Ensign Group, Inc. · Updated 2026-10-19
BBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BBIO currently ranks higher by quality score.
| BBIO | ENSG | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $66.39 | $176.63 |
| 12-month range | $53.81–$90.17 | $147.13–$215.83 |
| Rank by discount to fair value | — | #44 of 108 Healthcare |
| Rank by quality score | #133 of 301 Healthcare | #134 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: BBIO fair value analysis · ENSG fair value analysis